Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.
Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell arteritis (GCA), a debilitating autoimmune disease affecting the arteries. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results